


ALEXION 1850 UPDATES: PHASE 3 TRIALS FOR ALEXION'S NEW ENZYME REPLACEMENT THERAPY (ALXN1850) ARE NOW UNDERWAY

Phase 3 trials for Alexion's new enzyme replacement therapy (ALXN1850) are now underway. There are 20 sites across the United States and three different studies are being conducted.

The studies and inclusion/exclusion criteria are as follows:



Hickory Study

- Adolescents/Adults - 12 yrs +
- Documented diagnosis HPP
- NOT ever received Strensiq
- NOT have a new fracture within 12 weeks before 1st dose (excludes microfractures)

Detailed study information can be found [here](#)

Chestnut Study

- Child 2 - 12 yo
- Documented diagnosis of HPP
- HAS received Strensiq
- NOT have a new fracture within 12 weeks before 1st dose (excludes microfractures)
- includes adolescents and adults who are drug-naïve (have not previously been treated)

Detailed study information can be found [here](#)

Mulberry Study

- Child 2 - 12 yo
- Documented diagnosis of HPP
- NOT ever received Strensiq
- NOT have a new fracture within 12 weeks before 1st dose (excludes microfractures)

Detailed study information can be found [here](#)